DEVELOPMENT OF A NEW TRIVALENT CHELATING AGENT AND STUDY OF ITS COMPLEXATION TO FORM A COMPLEX WITH OXORRHENIUM(V)

Abstract

This project consists of the synthesis and characterization of a trivalent and polydentate ligand (H3L), developed to form an oxorenium(V) complex. This complex functions as a non-radioactive model for oxotechnetium(V) analogs, given its importance in nuclear medicine, especially in the diagnosis and treatment of cancer. The ligand was designed to occupy all coordination positions around the rhenium metal center, forming a hexacoordinated complex. Aldehyde functions located in the ligand enable bioconjugation reactions, ensuring specificity. The synthesis of the H3L ligand involved a reductive amination reaction followed by alkylation under an inert atmosphere, obtaining H3L as a solid after solvent removal under vacuum. The polydentate ligand was characterized by spectroscopic methods, FT-IR and ¹H and ¹³C NMR, and is being studied regarding a coordination reaction for the formation of an oxorrhenium(V) complex by reaction from [ReOCl3(PPh3)2]. The H3L ligand was successfully obtained and structurally characterized. After completing the characterization of the formed oxorrhene complex, further studies include labeling with technetium-99m and bioconjugation with tumor-specific biomolecules, aiming at clinical applications in oncological nuclear medicine.